Quick Search (by title or disease)
  

Go to Advanced Search for more options.

Clinical Trials Help

Contact our Cancer Information Line nurse with your questions about open or upcoming clinical trials, second opinions, or patient referrals.
ccinfo@umn.edu • 612-624-2620 • 1-888-226-2376

Hematologic malignancies Clinical Trials

Protocol Number Title
1999LS060
MT1999-14 Unrelated or partially matched allogeneic donor stem cells for lymphoma, myeloma, and chronic lymphocytic leukemia
2003NT036
ALTE03N1 Key Adverse Events After Childhood Cancer (COG study)
2005LS036
MT2005-02 Transplantation of Unrelated Donor Umbilical Cord Blood in Patients with Hematological Malignancies Using a Non-Myeloablative Preparative Regimen
2005LS043
MT2005-10 Transplantation of Unrelated Umbilical Cord Blood for Patients with Hematological Diseases with Cyclophosphamide/Fludarabine/Total Body Irradiation Myeloblative Preparative Regimen
2009NTUC056
Childhood Cancer Survivor Study
2010NTLS145
MT2007-05R Late Effects in Survivors of Cancer, Stem Cell Transplantation or Blood Disorders
2012CG091
COG ADVL1212 - A Phase I Study of Crizotinib in Combination with Conventional Chemotherapy for Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma. ADVL1212 Study Chair: NIH COG Phase I Grant (UMCA097452) ADVL1212 - Pfizer No. WS2274618
2012OC065
MT2012-11C: Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
2013LS023
MT2014-23R: Prevention of Bone Loss after Pediatric Hematopoietic Cell Transplantation
2013LS081
HM2013-24: Study of the ADAM17 Inhibitor INCB7839 Combined With Rituximab After Autologous Hematopoietic Cell Transplantation (HCT) For Patients With Diffuse Large B Cell Non-Hodgkin Lymphoma (DLBCL)
2013LS126
MT2013-37R: Voriconazole therapeutic drug monitoring in pediatric hematopoietic stem cell transplant patients
2013NTUC039
BMT Long-Term Follow-up Study -2
2013OC003
MT2013-06C : Treatment of graft Failure after HSCT
2013UC004
MT2015-09R: A Phase II Randomized, Placebo-controlled, Multicenter Trial to Evaluate Protective Function of an Optimized Dose of CMVPepVax in Recipients of an Allogeneic Hematopoietic Stem Cell Transplant
2014CG023
COG ADVL1312 - A PHASE 1/2 STUDY OF AZD1775 (MK-1775 , IND# 121422) IN COMBINATION WITH ORAL IRINOTECAN IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY SOLID TUMORS
2014CG036
COG ADVL1411 - A Phase 1/ 2 Study of BMN 673 (IND# 121510), an Oral Poly(ADP-Ribose) Polymerase Inhibitor, Plus Temozolomide in Children with Refractory or Recurrent Malignancies
2014CG089
COG AALL1231 - A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy)
2014LS020
MT2014-12:Phase I/II Study of Human Chorionic Gonadotropin and Epidermal Growth Factor Supplementation (Pregnyl?) to Support Tolerance and Repair As Adjunct Therapy in High-Risk or Refractory Acute Graft-Versus-Host Disease
2014LS093
HM2014-26 DT2219 immunotoxin for the treatment of relapsed or refractory CD19 (+) and/or CD 22 (+) B-lineage leukemia or lymphoma
2014NTLS071
Family-based studies of susceptibility to early onset disease
2015CG012
COG ADVL1412 - A Phase 1/2 Study of Nivolumab (IND# 124729) in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab Additional Title: ADVL1412-Bristol-Myers Squibb Company
2015CG031
ACCL1333/CV185-155 - A Phase III Randomized, Open Label, Multi-center Study of the Safety and Efficacy of Apixaban for Thromboembolism Prevention versus No Systemic Anticoagulant Prophylaxis during Induction Chemotherapy in Children with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoma (T or B cell) Treated with Pegylated (PEG) L-Asparaginase
2015CG175
COG ADVL1416 - A PHASE 1 STUDY OF RAMUCIRUMAB, A HUMAN MONOCLONAL ANTIBODY AGAINST THE VASCULAR ENDOTHELIAL GROWTH FACTOR-2 (VEGFR-2) RECEPTOR IN CHILDREN WITH REFRACTORY SOLID TUMORS, INCLUDING CNS TUMORS "ADVL1416 ? Eli Lilly and Company"
2015LS149
MT2015-17 :Transplantation of Umbilical Cord Blood from Unrelated Donors in Patients With Hematological Diseases Using a Non-Myeloablative Preparative Regimen
2015LS152
MT2015-32 : Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning (RIC) for the Treatment of Hematological Diseases
2015NTIS003
MT2015-16R:Novartis CCTL019A2205B; MT2015-16R: Long Term Follow-Up of Patients Exposed to Lentiviral- Based CD19 directed CART Cell Therapy
2015NTIS093
MT2015-21R: A follow-up study that evaluates the safety and clinical outcomes of subjects who have undergone hematopoietic stem cell transplantation with HSC835 (expanded umbilical cord blood hematopoietic stem cells)
2015NTLS018
MT2015-08R: Microbial, Graft and Host Interactions in Hematopoietic Cell Transplantation Reducing sepsis-related mortality in cancer patients through microbiome therapy
2015NTLS158
An advance care planning intervention for adolescent and young adult patients undergoing bone marrow transplant
2016CG084
COG ALTE1621: Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) Trial Additional Title: NIH Grant 1R01CA196854: ALTE1621
2016CG095
MT2016-13 :A Randomized, Phase II, Multicenter, Open Label, Study Evaluating Sirolimus and Prednisone in Patients with Refined Minnesota Standard Risk, Ann Arbor 1/2 Confirmed Acute Graft-Versus-Host Disease (CTN 1501)
2016CG156
COG ADVL1513 - A Phase 1 Study of Entinostat, an Oral Histone Deacetylase Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
2016IS005
AN OPEN-LABEL, RANDOMIZED, ADAPTIVE, TWO-ARM, MULTICENTER TRIAL TO EVALUATE PHARMACOKINETICS AND PHARMACODYNAMICS OF TWO DOSES OF OSELTAMIVIR (TAMIFLU?) IN THE TREATMENT OF INFLUENZA IN IMMUNOCOMPROMISED CHILDREN LESS THAN 13 YEARS OF AGE, WITH CONFIRMED INFLUENZA INFECTION
2016IS041
HM2016-16 : Multicenter Expanded Access Protocol of Allogeneic Epstein-Barr Virus Cytotoxic T Lymphocytes (EBV-CTLs) for Patients with EBV-Associated Viremia or Malignancies for Whom There are No Appropriate Alternative Therapies
2016LS132
MT2016-11C: Autologous Stem Cell Transplant In Patients with Hodgkin Lymphoma (HL) and Non-Hodgkin Lymphomas (NHL)
2016NTUC082
Prospective Symptom Assessment in Children with Advanced Cancer
KIN-2016-25209
The Development of Limb Position Sense during Childhood

37 trials displayed